(Q46683819)

24 December 2017

title

Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning (English)

1 reference

24 December 2017

1 reference

1 reference

2

John R Mascola

1 reference

24 December 2017

3

Gary J Nabel

1 reference

24 December 2017

Peter D. Kwong

series ordinal

1

object named as

Peter D Kwong

1 reference

24 December 2017

publication date

1 September 2013

1 reference

24 December 2017

Nature Reviews Immunology

published in

1 reference

24 December 2017

volume

13

1 reference

24 December 2017

issue

9

1 reference

24 December 2017

page(s)

693-701

1 reference

24 December 2017

Designing tomorrow's vaccines

cites work

1 reference

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

31 March 2020

1 reference

The role of antibodies in HIV vaccines

31 March 2020

1 reference

Induction of immunity to human immunodeficiency virus type-1 by vaccination

31 March 2020

1 reference

The immune response during acute HIV-1 infection: clues for vaccine development

31 March 2020

1 reference

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

31 March 2020

1 reference

GP120: target for neutralizing HIV-1 antibodies

31 March 2020

1 reference

The Antibody Response against HIV-1

31 March 2020

1 reference

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

31 March 2020

1 reference

Antibody neutralization and escape by HIV-1

31 March 2020

1 reference

Antibody vs. HIV in a clash of evolutionary titans

31 March 2020

1 reference

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

31 March 2020

1 reference

Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection

31 March 2020

1 reference

Characteristics of the earliest cross-neutralizing antibody response to HIV-1.

31 March 2020

1 reference

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals

31 March 2020

1 reference

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

31 March 2020

1 reference

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

31 March 2020

1 reference

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

31 March 2020

1 reference

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

31 March 2020

1 reference

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

31 March 2020

1 reference

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals

31 March 2020

1 reference

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection

31 March 2020

1 reference

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

31 March 2020

1 reference

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

31 March 2020

1 reference

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

31 March 2020

1 reference

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

31 March 2020

1 reference

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

31 March 2020

1 reference

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

31 March 2020

1 reference

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

31 March 2020

1 reference

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

31 March 2020

1 reference

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

31 March 2020

1 reference

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

31 March 2020

1 reference

Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting

31 March 2020

1 reference

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

31 March 2020

1 reference

Broad neutralization coverage of HIV by multiple highly potent antibodies

31 March 2020

1 reference

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

31 March 2020

1 reference

Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies

31 March 2020

1 reference

Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design

31 March 2020

1 reference

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

31 March 2020

1 reference

The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?

31 March 2020

1 reference

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

31 March 2020

1 reference

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

31 March 2020

1 reference

Defining the Protective Antibody Response for HIV-1

31 March 2020

1 reference

Broadening our view of protective antibody responses against HIV.

31 March 2020

1 reference

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

31 March 2020

1 reference

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

31 March 2020

1 reference

Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies

31 March 2020

1 reference

Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies

31 March 2020

1 reference

Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

31 March 2020

1 reference

Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors

31 March 2020

1 reference

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1

31 March 2020

1 reference

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

31 March 2020

1 reference

Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16

31 March 2020

1 reference

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

31 March 2020

1 reference

Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire.

31 March 2020

1 reference

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

31 March 2020

1 reference

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

31 March 2020

1 reference

Enhanced HIV-1 neutralization by antibody heteroligation

31 March 2020

1 reference

Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans

31 March 2020

1 reference

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

31 March 2020

1 reference

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

31 March 2020

1 reference

The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes

31 March 2020

1 reference

Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes

31 March 2020

1 reference

HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane

31 March 2020

1 reference

Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region

31 March 2020

1 reference

Antibodies, viruses and vaccines

31 March 2020

1 reference

Neutralizing antibodies to HIV-1 induced by immunization.

31 March 2020

1 reference

Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape

31 March 2020

1 reference

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

31 March 2020

1 reference

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

31 March 2020

1 reference

Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens

31 March 2020

1 reference

Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation

31 March 2020

1 reference

Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated

31 March 2020

1 reference

Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs

31 March 2020

1 reference

Prospects for an HIV vaccine: leading B cells down the right path

31 March 2020

1 reference

B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study

31 March 2020

1 reference

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies

31 March 2020

1 reference

Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody

31 March 2020

1 reference

Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics

31 March 2020

1 reference

Genomically humanized mice: technologies and promises

31 March 2020

1 reference

High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site

31 March 2020

1 reference

Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes

31 March 2020

1 reference

Shaping of human germline IgH repertoires revealed by deep sequencing

31 March 2020

1 reference

Therapeutic antibodies for autoimmunity and inflammation

31 March 2020

1 reference

A review of palivizumab and emerging therapies for respiratory syncytial virus

31 March 2020

1 reference

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

31 March 2020

1 reference

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

31 March 2020

1 reference

Enhanced antibody half-life improves in vivo activity

31 March 2020

1 reference

HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes

31 March 2020

1 reference

Antibody-based protection against HIV infection by vectored immunoprophylaxis

31 March 2020

1 reference

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

31 March 2020

1 reference

Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer

31 March 2020

1 reference

Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility

31 March 2020

1 reference

HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes

31 March 2020

1 reference

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

31 March 2020

1 reference

Elicitation of structure-specific antibodies by epitope scaffolds

31 March 2020

1 reference

Structural definition of a conserved neutralization epitope on HIV-1 gp120

31 March 2020

1 reference

Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold

31 March 2020

1 reference

Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04

31 March 2020

1 reference

Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.

31 March 2020

1 reference

Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120

31 March 2020

1 reference

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23969737

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23969737

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23969737

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRI3516

1 reference

24 December 2017

1 reference

24 December 2017